Results 111 to 120 of about 10,907 (165)
Some of the next articles are maybe not open access.
The History and Future of Probenecid
Cardiovascular Toxicology, 2011Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either.
Michael Tranter +2 more
exaly +3 more sources
Clinical Pharmacokinetics of Probenecid
Clinical Pharmacokinetics, 1981A review of the clinical applications and of the disposition of probenecid in man, including drug interactions, is presented. Probenecid is the classical competitive inhibitor of organic acid transport in the kidney and other organs. There are 2 primary clinical uses for probenecid: as a uricosuric agent in the treatment of chronic gout and as an ...
R F, Cunningham +2 more
openaire +2 more sources
Naproxen‐probenecid interaction
Clinical Pharmacology & Therapeutics, 1978Probenecid induced major alterations in the half‐life. renal clearance, and metabolism of naproxen. In 6 healthy subjects who received 500‐mg single oral doses of naproxen alone and (following two days of probenecid loading) with 500 mg of probenecid 4 times a day, there was an increase in naproxen plasma half‐life from the normal 14 to 37 hr.
R, Runkel +4 more
openaire +2 more sources
Pharmacokinetics of probenecid in sheep
Journal of Veterinary Pharmacology and Therapeutics, 1985Guerrini, V.H., Filippich, L.J., English, P.B., Schneider, J., Cao, G.R. & Bourne, D.W.A. Pharmacokinetics of probenecid in sheep. J. vet. Pharmacol. Therap. 8, 128–135.Six Merino ewes were given 1g (27g/kg) probenecid by the intravenous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) routes. After i.v.
GUERRINI, V. H. +5 more
openaire +4 more sources
Journal of Forensic Sciences, 1992
Abstract A death following deliberate ingestion of approximately 75 g of probenecid in a 36-year-old man is described. Tissue concentrations of probenecid were highest in serum (710 mg/L) and liver (550 mg/kg). Probenecid was also detected in vitreous and bile. Ethanol was also detected in blood at 0.13 g/100 mL.
I M, McIntyre +3 more
openaire +2 more sources
Abstract A death following deliberate ingestion of approximately 75 g of probenecid in a 36-year-old man is described. Tissue concentrations of probenecid were highest in serum (710 mg/L) and liver (550 mg/kg). Probenecid was also detected in vitreous and bile. Ethanol was also detected in blood at 0.13 g/100 mL.
I M, McIntyre +3 more
openaire +2 more sources
Probenecid-clofibrate interaction
Clinical Pharmacology and Therapeutics, 1981Clofibric acid disposition was studied in four healthy men after 1 wk of clofibrate ingestion (500 mg orally every 12 hr) with and without probenecid (500 mg orally every 6 hr). Mean (+/- SD) free clofibric acid plasma concentration in the four subjects over a dosage interval at steady state was 2.5 +/- 0.03 mg/1 before and 9.05 +/- 1.09 mg/1 after the
J R, Veenendaal +2 more
openaire +2 more sources
Journal of Pharmaceutical Sciences, 1993
Probenecid (PB) is believed to interact with the chiral nonsteroidal anti-inflammatory drug ketoprofen (KT) through competition for glucuronide conjugation and subsequent renal and/or biliary excretion of formed KT conjugates. It is unknown whether the interaction is dependent on PB concentration and whether both KT enantiomers are affected to the same
E L, Palylyk, F, Jamali
openaire +2 more sources
Probenecid (PB) is believed to interact with the chiral nonsteroidal anti-inflammatory drug ketoprofen (KT) through competition for glucuronide conjugation and subsequent renal and/or biliary excretion of formed KT conjugates. It is unknown whether the interaction is dependent on PB concentration and whether both KT enantiomers are affected to the same
E L, Palylyk, F, Jamali
openaire +2 more sources